InDevR and Sino Biological Team Up to Deliver Multiplexed Analytical Solutions for mRNA Vaccine and Cell & Gene Therapy

Share This Post

Partnership addresses biopharmaceutical industry’s urgent need for improved in-process and QC testing tools for these rapidly evolving application fields

InDevR, Inc., a leader in analytical solutions for vaccine in-process and quality control testing, and Sino Biological, Inc., a biotechnology company listed on the Shenzhen stock exchange subsidiary ChiNext (SZSE: 301047) specializing in biological research reagents and related technical contract research services, today announced a new partnership to speed development of multiplexed assays for a broad range of vaccine, mRNA therapies and cell and gene therapy applications.  

Through this partnership, Sino Biological’s catalog of high-quality antibodies, antigens, and other reagents are available for use on InDevR’s VaxArray Platform. Biopharmaceutical companies worldwide currently employ the VaxArray Platform’s multiplex assay capabilities in their vaccine testing to simplify, standardize and speed novel vaccine development, optimization of existing formulations and production scale-up. The two companies aim to accelerate the development and deployment of multiparametric analytical tools to aid researchers in driving advancements in mRNA, vaccine development and the rapidly evolving field of cell and gene therapy.

Since 2003, InDevR’s core focus has been to deliver innovative analytical tools for the vaccine industry. “Moving forward, our goal is to leverage that expertise to address the urgent need for improved analytical tools for cell and gene therapies and mRNA vaccine testing. Our partnership with Sino Biological, with their extraordinary breadth and depth of offerings and commitment to quality, will drive new product development and empower our customers to design their own multiplex assays with ease,” said Dr. Kathy Rowlen, CEO of InDevR.

Experts in recombinant protein production and antibody development, Sino Biological is equally enthusiastic about the collaboration. "We are thrilled to partner with InDevR to enhance the capabilities of their VaxArray Platform," Sino Biological Chief Business Officer Dr. Rob Burgess stated. "Our comprehensive range of quality reagents, combined with InDevR's cutting-edge analytical technology, promises to deliver superior solutions for in-process and quality control testing in the biopharmaceutical industry."

About InDevR

InDevR is a leader in innovative solutions for in-process, QC, and release testing of vaccines. Committed to enhancing the speed and accuracy of vaccine and other biological product characterization, InDevR’s products and services are trusted by leading pharmaceutical companies and research institutions around the globe.

About Sino Biological

Sino Biological is an international reagent supplier and contract research service provider. The company specializes in recombinant protein production and antibody development. All of Sino Biological's products are independently developed and produced with a stringent quality management system, and include unique bioreagents addressing areas such as cell therapy, stem cell, and infectious disease research. In addition, Sino Biological offers contract research production services for the custom development of full-length, bioactive proteins and high-affinity antibodies, along with other services. To learn more about Sino Biological, visit www.sinobiological.com, follow the company on LinkedIn or @SinoInc on Twitter.

Forward-Looking Statements

Certain statements in this document are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act. These statements are based on InDevR and Sino Biological management's current expectations and are subject to uncertainty and changes in circumstances. Actual results may differ materially from those included in these statements due to a variety of factors, over which neither InDevR nor Sino Biological has control. InDevR and Sino Biological assume no obligation to update these forward-looking statements and do not intend to do so.

For media inquiries or partnership opportunities, please contact:

InDevR, Inc.

Craig Hoechstetter
Vice President, Sales & Marketing
csh@indevr.com

Sino Biological, Inc.

gmo@sinobiological.cn

www.sinobiological.com

Contact Information:
Craig Hoechstetter
Vice President, Sales and Marketing
csh@indevr.com
Related Files
InDevR and Sino Biological PR-final

Related Images


Original Source: InDevR and Sino Biological Team Up to Deliver Multiplexed Analytical Solutions for mRNA Vaccine and Cell & Gene Therapy

Related Posts

Kids Get in Free: High School Baseball National Championship Series, Presented by Stinger Sports, Set for June 27-30 at Charles Schwab Field, Omaha, NE

The best-of-the-best high school baseball players from across the country are coming to Omaha. See the stars of tomorrow battle it out on the biggest stage. ...

FTC Data Shows Major Increases in Cash Payments to Government Impersonation Scammers

New Federal Trade Commission data reveals that government impersonation...

Introducing $UTHX, the Preeminent Metaverse Token on the Solana Blockchain

Utherverse (Utherverse.io) announces the August 2024 launch of $UTHX Utherverse Utherverse LOS ANGELES, June 14, ...

SWTHZ (SweatHouz) Appoints Dr. Susanna Søberg, PhD as Lead Science and Education Advisor

ATLANTA, June 13, 2024 (Newswire.com) - SWTHZ, the leader in boutique wellness and contrast therapy, is excited to announce the appointment of Dr. Susanna Søb...

Two Leading Student Transportation Technology Groups Announce Integration to Serve Joint Customers

Bytecurve and BusPlanner integration delivers opportunity for improved performance for hundreds of school bus fleets ...
green agriculture project
- Part of VUGA Media group -best seo company